Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,280 across all filing types
Latest filing 2025-02-06 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
关于被债权人申请预重整的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding a creditor's application for pre-reorganization (pre-insolvency restructuring) due to the company's inability to pay debts and the potential for judicial reorganization. It includes legal references, financial data, risk warnings about delisting and bankruptcy, and the company's response and plans. The document is not a full financial report but a regulatory announcement about a significant legal and financial event affecting the company. It does not contain comprehensive financial statements or quarterly/annual report data but focuses on the legal and operational implications of the creditor's application and potential restructuring. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-02-06 Chinese
2024年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a 2024 annual performance forecast (业绩预告) for Guangzhou Xiangxue Pharmaceutical Co., Ltd. It provides estimated financial results for the full year 2024, including expected net loss ranges and explanations for the performance changes. The document explicitly states that the data are preliminary estimates by the company's finance department and have not been audited yet. It also mentions that the final audited results will be disclosed in the 2024 annual report. The document length is short (1302 characters) and serves as a forward-looking earnings guidance rather than a full financial report. This type of document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results or forecasts with key highlights only, not a full annual report or audited financial statement. FY 2024
2025-01-15 Chinese
2024年第二次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2024 second extraordinary shareholders meeting of Guangzhou Xiangxue Pharmaceutical Co., Ltd. It includes information about the meeting date, voting methods, attendance, voting results on specific proposals, and legal opinions confirming the meeting's compliance with laws and regulations. The content focuses on the official voting results and decisions made by shareholders during the meeting. There is no indication that this is a full annual or interim report, audit report, or other financial report. The document is not a mere announcement of a report publication but a formal disclosure of voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters but contains substantive voting results, not just a notice or link to a report, so it is not an RPA or RNS filing.
2024-12-30 Chinese
2024年第二次临时股东会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of the 2024 second extraordinary general meeting (临时股东会) of Guangzhou Xiangxue Pharmaceutical Co., Ltd. It details the legality and validity of the meeting's call, attendance, and voting process, including the approval of specific resolutions. The document is not a financial report, earnings release, or management discussion but a legal opinion on the shareholder meeting process and results. This type of document corresponds to a Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and related shareholder meeting information.
2024-12-30 Chinese
关于累计诉讼事项的公告
Legal Proceedings Report Classification · 95% confidence The document is a detailed announcement by 广州市香雪制药股份有限公司 regarding cumulative litigation matters over the past twelve months. It includes extensive information about ongoing lawsuits, arbitration cases, involved parties, case progress, and amounts involved. The document references regulatory requirements from the Shenzhen Stock Exchange listing rules and provides a comprehensive table of litigation cases with financial impact. It explicitly states that the impact on profits is uncertain and that the company is actively managing these legal matters. There is no indication that this is a full financial report, audit report, or earnings release. Instead, it is a regulatory announcement focused on legal proceedings and their potential impact on the company. Given the detailed nature of the litigation update and the focus on legal matters, the document fits best under the category of Legal Proceedings Report (LTR). The document length (9016 characters) and content confirm it is not a brief announcement or certification but a substantive report on legal issues.
2024-12-13 Chinese
第九届监事会第十八次会议决议公告
Board/Management Information Classification · 90% confidence The document is a resolution announcement from the Supervisory Board of Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the reappointment of an accounting firm. It includes details about the meeting, voting results, and compliance with company law. The document does not contain financial statements or detailed audit results but announces a decision related to audit services. It is not a full audit report or annual report but an announcement of a board decision related to audit firm appointment. Therefore, it fits best under Board/Management Information (MANG) as it concerns a governance decision by the supervisory board.
2024-12-13 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.